GOLDEN, Colo. – Dec. 5, 2017 – PharmaJet® Inc., the maker of needle-free injection technology, announced today that the first ever human clinical study of an mRNA rabies vaccine successfully showed immunogenicity when administered with their needle-free injection devices.
Read more
Golden, Co. — Jan. 4 , 2017 — PharmaJet, the maker of innovative, needle-free injection technology, was featured on a CBS 60 Minutes segment concerning the National Institutes of Health DNA vaccine clinical trial for the Zika virus.
Read more
GOLDEN, Colo. — Oct. 25, 2016 — PharmaJet today announced a collaboration with Vaccibody AS to provide needle-free injection technology for the study of a vaccine to eradicate HPV. This disease is the main cause of cervical cancer affecting 530,000 women globally annually
Read more
Golden, Co. — August 3, 2016 — PharmaJet, the maker of innovative, needle-free injection technology, announced that the National Institutes of Health will use the PharmaJet Stratis® needle-free device in a DNA vaccine clinical trial for the Zika virus. DNA vaccines are the way of the future. Unlike traditional vaccines,
Read more
GOLDEN, Colo. – Feb. 22, 2013 – PharmaJet Inc. has entered into a collaboration agreement with CureVac GmbH for delivery of CureVac’s mRNA-based vaccine portfolio including targets in oncology and infectious diseases, using the PharmaJet needle-free jet injector platform.
Read more